Webinar · On demand

Under Pressure: How Aktiia Brought Their Continuous BP Device to Global Markets with high quality data

Aktiia CMO Jay Shah and Castor CEO Derk Arts discuss validating a continuous blood pressure wearable and structuring clinical studies for global markets.

42 min · Recorded 27 March 2024

  • Dr. Jay ShahChief Medical Officer, Aktiia
  • Derk ArtsCEO & Founder, Castor
  • Dr. Jay ShahChief Medical Officer, Aktiia
  • Derk ArtsCEO & Founder, Castor

About this webinar

In this webinar, Aktiia Chief Medical Officer Jay Shah joins Castor CEO Derk Arts to discuss how Aktiia brought its continuous, wrist-worn blood pressure monitor to seven European markets. Built for medical device developers, clinical operations leaders, and trial sponsors, the session examines why traditional episodic cuff readings fail to address global hypertension control rates, which remain at 20 percent worldwide. Shah details how Aktiia combines off-the-shelf optical sensors with proprietary cloud algorithms developed over 20 years to capture hundreds of measurements per week. He also outlines Aktiia's three-part clinical evidence strategy across pivotal regulatory studies, telehealth outcome trials, and multi-decade longitudinal cohorts, explaining how flexible data capture through Castor supports regulatory validation and digital biomarker discovery.

Key takeaways

  • Despite widely available generic medications, global hypertension control sits at 20 percent because episodic cuff readings fail to engage patients or guide personalized treatment.
  • Aktiia uses standard off-the-shelf photoplethysmography sensors and a three-way accelerometer at the wrist, relying on cloud-based optical signal processing algorithms to generate medical-grade blood pressure readings during periods of stillness.
  • Regulatory validation for continuous blood pressure monitoring requires proving accuracy across systolic ranges from 80 to 200 and diastolic ranges from 40 to 120, as well as across Fitzpatrick skin tone scales one through six, BMI, and hair density.
  • Aktiia structures its clinical development into three distinct tracks: pivotal studies for CE mark and FDA approvals, outcome studies for remote monitoring and emergency prevention, and longitudinal cohort studies.
  • Through a general-purpose API, Aktiia integrates time-stamped blood pressure and heart rate streams into platforms like Castor to combine continuous physiological signals with genomic, imaging, and health record datasets.
Full transcript

Hey. Good morning, everyone, and welcome to this, LinkedIn live event. I have with me here, Jay Shah, chief medical officer at Oktia.

And we're gonna be talking today about their continuous, blood pressure measuring device and, about how they got that to the market, how they, made sure there was scientific rigor behind that, and just exactly, how you set up a coherent data capture strategy for a new device. Jay, can you do a quick intro about yourself and about, about Oktia?

Sure. Thanks very much for having me here, Derk. It's a pleasure to be here. So as as you said, Jay Shyam, I'm a cardiologist by background. I practice in the US for over fifteen years at Mayo Clinic, Mass General, and I've been with Aktiia now for about two and a half years as the chief medical officer, doing sort of many different aspects of the overall, functions in the company from business development, partnerships, product development design, r and r and d. And under that is the clinical development strategy, as well as some regulatory work.

And Aktiia is a company that was founded, six years ago now. It's a Swiss company, and our founders have been working on this technology for over twenty years before, at CSEM, in in Switzerland.

And Aktea, their technology and now what we have deployed in now seven markets across Europe is is bringing the what we think is the world's first widely available at home, as you said, continuous blood pressure technology to scale.

And that's really our focus, at Aktiia.

That's amazing. And, as, all of us may know or may not know, I I, I'm actually also a medical doctor, but I I never ended up practicing in in the hospital because I did my PhD and then stayed with, stayed with Gaster.

But, in my PhD and also the work I did, when I was working in the hospital, in med school, it was very obvious. You know, if you look at any risk stratification score to predict the risk for for anything, it almost always includes high blood pressure or or hypertension. And so, I think it's safe to say that we have been looking at a, a sort of epidemic of of hypertension globally for for years now, and it's actually very common in all, populations.

And being able to to measure that early and get to it early and also measure it continuously can be very powerful weapon, I think, in the prevention of of many diseases. Is that is that right, Jay? How do you look at the Yeah.

I mean, I think overall, thematically, you hit on a lot of points that are really, important and and sort of oftentimes different in how the traditional health care system, approaches and thinks about blood pressure. So as a cardiologist, we could see this all the time. But just to kind of give people the, frame of the scope of the problem, high blood pressure or hypertension affects one point four billion people globally.

In the US alone, it's something like a hundred and thirty million people.

Almost half of the adult population over the age of sixty five has or will develop hypertension.

And although commonly, it's thought about as a primary, input to cardiovascular disease like heart attacks, heart failure, arrhythmia, stroke, it actually affects many other organ systems, in different ways. And sometimes people may not have the same sort of recognition about how important it is, for example, in kidney disease, chronic kidney disease, kidney failure, in aortic aneurysms and a cause for a major and very common and and oftentimes, poorly diagnosed disease in dementia, or a type of dementia called vascular dementia that often kind of coexists or goes in tandem with with, cognitive decline.

Just as an example, and even in young women in pregnancy, there are significant complications during or after pregnancy that relate to high blood pressure. So it really spans multiple areas of, of disease states. It also spans multiple areas of therapy, therapeutic areas. So for example, on the in the oncology space, what we're seeing over the last few years are these really amazing novel therapeutic compounds for onco oncologic, therapies that a cause or effect, that they might have is high blood pressure.

So it's it's really an interesting dynamic, and it's an interesting time. And for many, many years, I would say even decades, their sort of innovation in blood pressure kinda stagnated over the last maybe twenty, thirty years.

Most of the drugs now are generic. It's pretty commonplace to kind of understand and how to treat it. But I would say in the last few years, there's been a real explosion of innovation, not just in in diagnostic and monitoring capabilities, which which we're really focused on, but also in the therapeutic areas are some really exciting new compounds, in using RNA and other and now procedures even, called renal denervation. So I think there's a lot of interest and and excitement now that that is sort of coming back in the field of blood pressure.

Yeah. I I agree. I actually had a a close friend who, did a PhD in renal So, I, I'm pretty pretty close to that. But back to back to you because, I mean, I think the good news is, right, evidence evidence based medicine delivered, I would say, in in the field of hypertension at least. But we have we have a lot of drugs in the markets. They're like you said, a lot of them are generics.

They work quite well. We actually have a pretty good understanding of what what drug we need to give to to who. Correct me if I'm wrong.

But I I I actually think that's that's gonna be the exception. That should be the should be the the rule, but there aren't that many diseases I think that are, covered so well at least with with drugs that are affordable and effective and, prescribed, you know, relatively well to to the right population. Right?

Well, you're right in some ways, and then some ways, I probably would disagree a little bit. So you're right. We have a tremendous, toolbox for hypertension.

We have cheap, generic, fairly widely available medications. We have lifestyle interventions that we know work generally. But, again, as you said, going back to the evidence base, the evidence base in blood pressure has has always been around large epidemiologic type disease, subsets of of of, datasets.

And one of the one of the failings of that is that we really don't know as a clinician.

I know the seven lifestyle interventions and the six medications that might work, but I don't know which one is gonna work for which person.

So everybody, generally, with very limited exceptions gets the sort of same approach.

And so what ends up happening is that it it it becomes this sort of one size fits all treatment. And, yeah, we can make some progress in that way. We it is reasonably successful. But I would say it's really far afield from sort of the the way that, for example, the the oncologic field is going where you have personalized, treatments based on specific molecules.

We don't have that in blood pressure. We everyone gets the same sort of treatment and the same, you know, lifestyle conversations and interventions. And the second part of that is is that it really isn't engaging for the for the for the person, the patient. You know, the the actual person who has high blood pressure gets this sort of very generic, diatribe from their physician, from expert societies and on, but it often doesn't mean much to them.

It doesn't doesn't affect them personally, which is why noncompliance in blood pressure medications is so high, which is why the use of traditional blood pressure cuffs and looking at their data is extremely poor across the world, and which is why therapeutic inertia by physicians is pretty significant in terms of actually change making changes to their, medication regimen because they don't generally have data because people aren't checking their blood pressure on a routine basis. And so what this leads to is that while we have the knowledge base to treat blood pressure really, really well, the global control rate, meaning the people who have their blood pressure under control, who have hypertension, is twenty percent.

One in five. And it's not much different in in sort of wealthier nations or more, you know, quote, unquote advanced nations. So in the US, the control rate's twenty six percent. So even though we have that knowledge, we're not really doing a great job as a system, in in really changing that paradigm.

Yeah. I see that. I see that. And I I that's actually I think where I want to go with this, with this with the setup. So thank you for very elaborately, filling that in because, I think, you know, even though we have, I think, treatments that we know work, are they prescribed sufficiently as how is, you know, how are people actually taking these drugs? And, are we prescribing to the right person to to to the right to patients?

And so I think there is a need in the market for for a better way to do things, and I think that's where your where your device, comes in. Right? Because Yeah. I think as far as I know, there's a lot of undiagnosed hypertension, of course.

And then there's a lot like you said, like, understanding on what could be the best treatment for someone. You know, maybe we need a new biomarker, perhaps a digital biomarker. I don't know. But, maybe you can tell us a little bit more about technology in the device.

Yeah. So, I mean, the the reason our founders have been working on this for such a long time, they have a personal interest, and and effect in in from blood pressure in their families.

And anyone who's really had this in their families, and pretty much everybody will, will either have it themselves or will have some family member who is affected by it, We'll very quickly see that that the way we look at blood pressure is is really kind of discordant from the how the disease of hypertension actually affects your body, meaning that we look at blood pressure in these really episodic snapshots. When you take a cuff, you put it on, you measure blood pressure, you get one reading at one moment in time. And, generally, most people, even with hypertension, only get one or two readings a year at most, and they really have no clue what is happening in between those readings.

And and that's really where there's a lack of, from a business term, product market fit for traditional cuffs in the monitoring space of blood pressure. And blood pressure is a dynamic variable that changes minute to minute, hour to hour, week to week, month to month. And so the idea of having something that's super easy to use, really, you know, built around the a person's life and and sort of their how they would consistently use something.

Easy to wear, really relatively simple to to kind of, you know, interact with it, and gives you two hundred measurements a week, eight hundred a month, and thousands and thousands if you wear it for longer periods of time. So you so not so much important to see that one, moment in time, what is the value, but what is your trend? What are your patterns? What what happens when you try one intervention or one medication or one you can see that cause and effect on a personal level. So you can go to one size fits all from one size fits all to personalized sort of treatment, cause effect, figuring out which interventions work for that person. So a good example for just to take one in the lifestyle space is is sodium reduction. Everybody knows, like, anyone who's you will know that, yes, lower sodium intake theoretically should help your blood pressure.

What what we don't and physicians, we all say it. Every single time someone comes in, we talk about lowering the sodium content, which is super difficult to do, by the way, because so sodium is in everything.

What we don't say and often don't even realize is that only fifty percent of people with hypertension are salt sensitive.

So for fully half the people we're making that recommendation to, it's not gonna help, and it makes no difference. And we have no idea which fifty percent that person is or, you know, are they self sensitive or are they not? So a tool that allows them to kind of test and see cause and effect for them, for their body, for their medications and their intervention is really what this the power of this sort of tool gets at. And that's what the the the rationale around the technology is. And and I guess a little bit of background on the technology itself, it's a simple, easy to wear device.

Charge it once every a little bit better?

The camera?

Yep. Yep. So it's a real it's a real sort of Swiss design.

Yeah. You know? It's a it's a little pod here with a bracelet around it.

A simple, easy to wear design lasts about ten days per battery charge, come it's rechargeable, obviously, and and you get, as I said, these measurements without having to think about it. You don't have to push a button. You don't have to do anything. You just keep it charged and wear it.

And you look on your smartphone, and and there's all the Oh, you gotta you gotta calibrate it.

Right?

You calibrate once a month. Yep. Once a month. Right now, once every thirty days, there's a calibration step with a cuff that we provide.

It's all goes through the app, and and there is a calibration step. Yes. Once every thirty days. We're working on getting rid of that calibration step, but right now, it's important and, it does, you know, is a requirement.

So I I wouldn't suffice for about, I think, three to six months because, you know, actually I actually remember hearing first about you when when we weren't even working together, when, you know, when a VC approached me because, you know, you were speaking about raising additional capital and, you know, obviously, I'm in the field as they say. And when I heard this, I was like, oh my god. Like, yes. Of course.

Like, this is, you know, this is a this is a no brainer. So I I also want to get access to the device. I want to understand, how it works. I've worked for a while, and I got it set.

You know, it's it's it's really impressive.

And I you know, maybe we have, I think, a lot of people here in the in the audience that are in medical device development. So, obviously, developing a device like this is is tricky, and I think it's good for them to, to understand what so where does this device take? Obviously, it's not implanted. We can see that it's sitting on your wrist.

So that that's pretty easy. There's also an app that I've used. Right? So in the app, you get these beautiful kind of charts where you see your your blood pressure kind of develops through the through the day.

There's then the calibration, of course. The app also triggers you to do that. The cuff, you know, it's a separate a separate device. Looks beautiful.

By the way, best looking sort of old school blood pressure monitor that I've seen, I think.

And, so but but but how does it work? Right? Like, so what what is the type of technology we're looking at here? Because I think in the audience, we we probably have a few people that are looking at similar technology stacks.

Right? There's an there's a cloud component in, let's say, in machine learning, or do we wanna say, I let's let's see with a machine learning component. There's a hardware. Can you speak a bit more about that and Sure.

And how you develop that?

So you already described most of the components of the hardware. You have the bracelet. You have the cuff. You have the charger. It all comes in one box. You get it all at the same time. You get the software and the app, as well, which, you know and it all comes for one cost.

The the technology itself, is different in that it works using what's called PPG or photo plethysmography.

Basically, it's using the green LED lights that most people have seen on on smartwatches and smart devices. There's there's two yeah. Similar to that, there's two of those in here. There's also an optical sensor, and there's a three way accelerometer. That's what's in here.

And nothing in here is proprietary. This is sort of all standard off the shelf, components.

And, but what they do is take the raw PPG signals from the wrist, from the skin on your wrist at very specific times. And there the only programming in here is firmware to really get appropriate times to try to take measurements.

And and then it takes those raw signals, goes through your phone, uploads it to the cloud. The cloud is where the algorithm that has been developed over twenty plus years now works on that, those raw PPG signals, which then are returned back to your phone and displayed as blood pressure and heart rate, medical grade blood pressure and heart rate.

And there really isn't an you know, the the the technology of the algorithm development, is really optical signal processing with some component of deep learning and machine learning.

And, and that's, you know, all I I mean, I can't really go into too much detail there. Most neither from a technical standpoint as well as that's really where our proprietary information is.

And but that's that's how we have developed the technology to the point where it's gotten the ability to get accurate enough to then get regulatory approvals across Europe.

So I I think there's there's a tone to it back here. I said, Nina, I'm I'm generally a very curious person. So, I mean, I I know my watch right now because I was wearing both. Right?

I was also wearing a Whoop at the time, so I like wearing sort of multiple wearables. I'm trying to sort of refer it back to to just my my Garmin, but it also has a PPG sensor. Right? So, basically, you're saying in theory I mean, let's, of course, assume your your model is, attuned or trained on the exact kind of sensor that you're using in this device.

We're saying it's generic sensor. So, theoretically, we should be able to even use RTF with with my Garmin watch at some point. You know? Is that is that possible because there are these generic components?

It is possible. It is on the road map. It's just it's a matter of actually, it gets complicated in a hurry once you start, working with, you know, third party large consumer electronics companies, because access to sensors, access to the lights from an app that's riding on top of their hardware, gets trickier. It is it is possible, though. We've already tested it on on six other devices. So we know we can eventually deploy the software and this approach using third party devices. It's just a matter of time and and, you know, working with those companies to do so.

Yeah. You know, we can talk about the business side of that, but, you know, that's that's super interesting. Right? I know Garmin has actually worked closely with a couple of partners who are actually sitting on their stack, and I mean, showing up in my app.

So I would love I would love for that to happen here too because then you you this is completely, like, mind blowing disruptive. But I think it already is. Right? And I think what I want the, the focus, to be on here is I feel like people would generally be drawn towards the hardware.

Okay. So this is the CE marked, you know, device. But, actually, what you're saying is is is it you know, it's it's basically SAMD to an extent. Right?

Because the true, the true intelligence, the true, innovation here is sitting in your proprietary, you know, twenty year old algorithms that's or at least not twenty year old, but, you know, developing a computer for twenty years, that's they can actually interpret that that information. So can you talk about the regulatory path there? Like, what's what did the regulators look at? Where were what was easy?

What was hard?

And and and sort of how did that how what was the journey?

Well, I can talk about the journey since I've been here. You know, the the the journey of the founders before the company was founded, obviously, was deeply this company is deeply rooted in science. So that's the first thing I would wanna start with to say is that these are two biomedical engineers that founded the company, that have done this research for over twenty years, and they only were comfortable commercializing it once they felt comfortable that they got to the point where where they felt comfortable that really they thought this could be accurate enough to be used in medical settings and health care settings.

The second part is is that regulatory is, obviously, as anyone in the medical device field or, you know, any sort of, pharmacological field knows is is the the the biggest, burden, opportunity, and barrier. So it really requires a significant amount of of rigor. And then, again, so coming back to the the sort of deeply rooted in science really gave us that mindset that we are going to have to do the hard work to to really get through regulatory agencies and bodies because you have to prove the science. You have to prove how it works. Now the regulatory submissions in broad strokes is that everything is taken into account. It's not right now, it's hardware, software, everything has to be considered in the regulatory submission, and that's the way it is gonna be, you know, for at least the near to midterm.

And and and they have there's very stringent criteria about accuracy.

There's very stringent criteria about study design, protocol, how you capture that data, how you analyze the data.

And so we have to fit within the sort of, context of that of those regulatory approvals. And I will say that when we talk about validation when we say the word validation, we talk about validation on an international standard used for regulatory approval. I think that word validation around blood pressure means a lot of different things for a lot of different people, and we talk about it in the most sort of stringent and rigorous way. That's how we think about it. So there's not much easy in regulatory, pathways, honestly.

Did you did you take the five ten k routes in the US or, a different So right now, we are approved in in we have CE Mark, and we're approved in some countries.

We do not yet have FDA approval.

We are working with the FDA currently, and I, you know, I I will share that, you know, we are looking at, early next year having our first, approval. I don't think I can go into too much detail into our regulatory strategy on this on this call, but it's, you know, we're actively in that process.

Yeah.

And then, of course, that's also what we're promised to get, which are actively, you know, running studies to, to capture to capture more data. So maybe we can we can talk about that a little bit because, you know, I so I'm, but I'm also sometimes skeptical skeptical about the innovations I see. And when I heard about your device for the first time, I was like, well, that sounds too too good to be true almost, you know, like, completely Mhmm.

New way of of measuring this continuously.

So I did a lot of research even before reaching out to, to get access to the device.

And, yeah, like you said, there's a ton of research there. Right? And I you can go on on Google Scholar and find those find those papers. Very interesting.

And I was like, okay. Well, you know, let's look at the sample size and everything else, but really just super solid. And and, honestly, that that's, you know, that should be the way, I think. Right?

That that's the way to do it, to really have, a very solid scientific base. So, and I'm I'm very happy that you're you're continuing that in your your approaching, you know, approval by the FDA as well. And so can you talk us talk to us a little bit about how, how you set up these studies? What what type of study are you running?

How are you how are you running them? Sure. And, yeah, if you wanna share a little bit about how how we use a Gasser, then work a little longer.

Yeah. Happy to. So the I would say I put our study, sort of strategy clinical study strategy into three buckets. The first bucket would be, pivotal studies for regulatory approval, And these are, you know, as as we just were talking about sort of to meet the very stringent requirements of all regulatory bodies around the world, and we do interact with, a number of them. Right now, we're focused on, the CE, sort of mark and their and their notified bodies that, work with that, which gives us access eventually to about forty countries and then, then the FDA. So right now we're focused on those two.

And so the pivotal studies are primarily to, expand our indications for use in the markets we're in or to get into, to get into a market that we are not getting.

So that's one bucket of studies. The second bucket of studies, I would say, are, are sort of, I would call them, outcome studies, meaning that using the technology in a very concrete way that's very understandable in today's context of blood pressure. So using the technology to lower blood pressure in a remote patient monitored, telehealth sort of setting, using the technology to look at preventing ER visits for hypertensive emergency patients paired with, sort of, you know, remote, visits and things like that. So very clear and easy sort of use cases that that we have investigators all around the world that are very interested in using this, and we we work with them, routinely on those studies.

And then the third bucket, I would say, is oftentimes, to me, the most interesting, the most exciting, which are sort of I call them sort of longitudinal cohort studies. So using the technology to capture these dramatic and multidimensional datasets of blood pressure, which no one's ever seen before. And oftentimes, we don't even know what they mean, but we can map, thousands of users out, and we can see how they interact with different sets of data.

And if we embed that data into longitudinal studies that are are cohort studies, a a good example would be, there's a study that we're working with out of Liechtenstein and, the PI is in McMaster University in Canada, and they're looking at eighteen hundred people for over twenty to thirty years and following them in all their health outcomes, including biomarker data, imaging data, health record data, on a and genomic data on this sort of timeline.

Now we're adding to that this multidimensional, blood pressure data. So we can see what the relationships are. We can see how that data interacts. And and then, hopefully, we can come up with insights that eventually can be more helpful so that in the future, we don't talk about blood pressure in just millimeters of mercury anymore.

We talk about it in patterns, in different metrics, in predictive, analytics, those kind of things. So these are the three buckets of studies. In each one of them, capturing data reliably and with high quality is exceedingly important, And that's really where, partnerships with with companies like like Castor come into play. And each one of them requires different types of data to be captured.

Each one of them requires slightly different not slightly, sometimes often dramatically different information. So having the ability to be flexible with different types of studies, is really important, and we've really, really found value in in working with Castor's platform to do that. In addition to that, I think the one of the other most critical, especially for a start up, is being flexible, being flexible to adapt even within a study. So studies going well or we wanna add a different set of dimensions of data.

Well, we need that that EC to be flexible with us. And and I think that's really what we see some of the major, advantages of using Castor and what where we feel really comfortable and, you know, with the platform. And then I think the the last thing, that I'll wanna mention just and then, of course, I'll let you talk, Derk. But the last thing I wanna mention is that, you know, we we also we are a small company, but we've been able to get regulatory approval in over seven markets in medical device, which is a dramatic testament to the company's, ability there and their sort of, ability to be aggressive and nimble and thoughtful all at the same time.

And we look for partners that are of similar mindset. And that's really where we feel we find other than the technical capabilities that I just mentioned. We find that mindset fit of the company and the group that we're working with so critical for us. And, again, that's really where we feel, you know, Castor excels.

So, you know, those are my my new.

Terrific. Thank thanks so much for that for that kind of work. That's a lot more than that I was expecting.

And, I do think it it provides an interesting bridge though because, you know, we do want to be a lot innovative as well as a company. And, of course, we are very interested in seeing how can we offer more options to to our customers. Right? So Castor is an API for a solution, and, a lot of our medical device customers use that when they have an SME type device to also push data into the platform alongside the clinical data being captured and alongside the ePRO that you need being captured, etcetera.

So really acting as a central repository for all these data streams to to come in. But that also, of course, means that, you can quite easily integrate, you know, digital biomarkers, etcetera, into clinical trials. And so, as I understood it, you know, you you see a lot of potential for for blood pressure. Right?

So if we just move away from from hypertension as a disease for a second, which is blood pressure, as a as a biomarker. And, obviously, that's you know, we are work together already. So is there is there a future where we can go and offer our customers, you know, your devices as as a way of of capturing that information in a in a trial. And then how what what would it take to to get there?

Not very much more, actually.

So we have already built a general purpose API for for at least blood medical grade blood pressure and heart rate cap that recapture on on our device.

And, and we have already had significant interest from, from third parties such as Castor and others and CROs that with the idea of being able to pull in, you know, highly, you know, reliable and accurate blood pressure heart rate data into a dataset that has many other, components to it. And and we think that blood pressure there is so much hidden in the blood pressure signals that we are currently not aware of. So we talk about hypertension, just this sort of binary threshold of one forty over ninety or one thirty over eighty or whatever it is. But the truth is in clinic as a physician, we often see people who have normal blood pressure that have some event in the future that clearly probably related to some blood pressure biomarker, some hidden signal there.

And the only way we can start to uncover those signals is to pair the blood pressure data, not just in hypertensive people, but all types of people with these other complex multimodality datasets. That's why I was really excited about these longitudinal cohorts because that's what we're doing. And and we wanna expand that to therapeutic areas, to medications, to, other medical device devices and interventions and procedures because the more data we can put together, the more insights we'll gain into the blood pressure as a biomarker. And so what are those signals?

What actually means something and what maybe doesn't mean something? The only way we'll know that is by combining these datasets together. And I think that's where, what you just described in as a as Castor's platform is pulling that complex data together is crucial in enabling them the analysis of that.

So, you know, and you don't have to answer this question, but, if if I am a, a sponsor and I'm going to use your device in my clinical file, do I get access to the raw PPG data, or what, what do I get access to?

No. Generally, no. We don't give people access to the raw PPD PPG data.

We do I mean, of course, I know what.

I mean, because you might as well just use another PPG sensor if you just want a PPG.

Yeah. If you just want PPG, then, you know, there there's a lot in there that that what we do that is proprietary, that our founders have built over. There's a lot of IP in there, and how we look at the PPG data. If you just want raw PPG signals, there's plenty of devices that can give you raw PPG signals.

I think the key is what do you do with those signals and how do you come up with blood pressure data? And that's really what has taken a tremendous amount of time and effort and, and infrastructure. So when we work with sponsors, who wanna partner in some regard, what we deliver to them right now and there's a couple things. But what the simplest thing we deliver is blood pressure, heart rate, date, and time stamped, with the continuous sort of frequency.

Yeah. Individual measurements with our continuous frequency. Now if they have data analysts that then can take that and pair it with their own other data and come up great, that's fine. That's there.

We also have a data analytics team. So sometimes sponsors come to us and say, can you do some of this data analysis? Because you are, you know, our our data analytics data science people are really experts at this. And we show them some multi modal multidimensional datasets that we can create, and they're super interested in that.

So then there's some some aspect of that that we that we agree on that we will provide sort of higher level types of datasets to them.

But, you know, again, at this point, we're we're small, and we're trying to grow, and we're trying to uncover these these sort of insights into blood pressure. So we'd rather partner with more serious partners than be too restrictive. We don't we don't we don't wanna be too restrictive, because that's gonna limit ourselves as well as just sort of the the incremental gains in knowledge. So, you know, and that goes against our mission. So we we try to make it all work. It's just we do have to be aware of where our value lies as a company and, you know, of course, almost all companies understand that and people get that.

Yeah. It makes a lot of sense. No. And I think that that's where the value lies from. I mean, that that's the whole point, to get continuous measurements at a certain interval.

So we're we're coming up all the time, and there's quite a few questions.

Oh, sure.

And everyone's very interested in, in in the device and what it can do. Are you seeing those questions, Jay? Yeah.

I can see them. Yep.

You wanna start with the hardest, the hardest one?

Okay. Sure.

What what's new? What's new about your device?

What's new about the device? Yeah. Okay.

There there really aren't any other devices on the market that that will give you medical grade blood pressure on a continuous fashion in an at home use, you know, from a easily worn device, that have I can send you the I did that research too.

Yeah. There there's but there but I will say to this to this person's question, there's a ton of noise. There is. And it's actually you know, if you go on Amazon and just put in watch that gives you blood pressure, thirty of them will come up for ten dollars each.

And and so there's a ton of noise, and and you have to distinguish and the the the users have to be, you know, sophisticated enough or do the work that you did. Eric's like, go in there. Look. Do they have regulatory approval?

Is this a gimmick? Are they just saying they do blood pressure? And there's a lot of apps that that are heart rate apps that are not regulatory approved. They say, we're a heart rate, blood pressure app.

But then you go into it, you buy it, you probably have to pay for it, and they say, well, get your blood pressure cuff from the store and then just manually input your data. So there's tons of noise there into the space, and and so we have to we have to be, you know, in our communication and marketing strategy, we have to, you know, figure out a way to to really, Yeah. You know, isolate ourselves in a different way. Exactly.

So any any chance you're going to allow Yeah. To deal with this productivity?

It it so the the the reason that we have a, three way accelerometer is that the signals the optical signals at the wrist are incredibly noisy.

And when your when your arm is moving or you're doing you're running or doing some walking even, the noise is so significant that we know that we're not gonna get good signals. So we would rather not provide really bad data than, to provide any you know, so we would just say we're not gonna. So that's what the three way accelerometer does. It gate gates the sensor from saying, let's take a measurement.

Now if the if the physical activity doesn't involve a lot of wrist motion, theoretically, you could imagine someone cycling or something like this, you could get some measurements during that activity. But for the majority of the measurements are going to be during a time of stillness. Doesn't have to be rest per se, but has to be stillness of your wrist. And that has to do with just data quality.

It's a we really won't get great data quality of the signals, and, again, we wanna make sure we provide the highest quality possible.

Yeah. That's what I remember probably more seventeen years ago or something now that I did my first research project in, South Africa UC, active meter, of course. Yeah. Like, the legendary the legendary wearable, I think, in the active breath.

And then yeah. And, you know, we get all this weird data. And then there's just patients, you know, brushing your teeth on with the with the dominant, and you put it on the dominant wrist if you know it's all not to. Yeah.

And, like, you know, noise, a lot of noise. Exactly.

Alright.

So, can you let's jump into the Let's see.

Yep. The range, validation, you have to so this is gets it, I mean, the question is valid, but this is where the regulatory agencies and the protocols for validation are extremely strict. You have to have a range of a certain number of patients from systolic down to eighty, up to two hundred, and diastolic, I think from forty to hundred and twenty. So, yeah, I mean, it covers the majority the vast majority of the of the physiologic range, and that's how that's the it's the same ranges that cuffs are validated in as well. So that's you have to have a and you have to prove accuracy across those ranges.

And just as a matter of other questions, you have to prove accuracy across different skin tones from Fitzpatrick scale one to six, so it's lightest to darkest skins, follicle density, hair density, or BMI, obesity, gender, all those things you have to prove accuracy in every single cohort of of users.

Yeah. If you thought you're gonna rush a PPG based device to the markets, think again. Yeah. Yeah.

It's not yes. It's no easy.

Yes, professor, just stay tuned. That's all I'll say about that. It's it's, yeah. Just stay tuned.

Actually, one of the feature requests too.

Yes. I I I found I think that, you know, to me to be honest, again, I'll I think I've given you enough praise for for for this advice. I think the thing that I know I know the most was just having to be still.

Like, I'm a very active Mhmm.

Person and sometimes, you know, it's fine.

But, like, I think I'm actually gonna measure, and I wanna I wanna know now. I know. I just have my cup of coffee.

Correct.

Give me give me my give me my measurements. But, I think in the end, if you just live, you actually get the data.

You gotta just keep track of what That that's the idea.

That's why we didn't initially enable it. We could have done it. I mean, that's why we didn't initially enable it, that way because we wanted we want to encourage people to look over the long term rather than those that decide it. But but we get that request quite a bit. It's it's, just just stay tuned, professor, please. Yeah.

We have three questions about the, API, I guess. One about integrating with hospital system, And then two more about, the API.

Yeah. API. It's a it's a general purpose built API.

So it'll it can integrate with any any third party, software with the appropriate again, I'm not technically so savvy here in how the API is constructed, but it'll it can integrate with any other, software, whether it's a web based software, whether it's an app, whether it's a EHR. It's a general purpose API. So it's not specific to any one partner.

Shame is plugged here, but there is actually not that many clinical trial platforms that have a Redflow API that you can easily integrate with. But Yeah.

I mean, it does require effort on the third party's part as well to set that up appropriately.

So it it does. Yeah. It is, but it is yeah. That's the answer.

Is can can it bind any documentation on your API, somewhere?

This is the conversation between our technical team and theirs. So it's like, right, we don't publish that. It's it's it's straightforward, but, it's not proprietary or anything. But if there's interested parties, then what we would do is just set up, meetings, between our team and theirs and, you know, sort out the technical aspects.

Yeah. Terrific. Well, we're over time here. Thanks for all the for all the questions, and, thanks for, for an amazing reception, Jay. I think we touched on a lot.

My my favorite type of, event, I will say. I would invite the audience to, to connect with us on on LinkedIn, to to to make sure to ask any follow-up questions. You know, if you wanna learn more about the API, you know, let's the team at t n o. I now know how to pronounce it. It's also helpful.

And, yeah, I just wanna thank the audience for for a great session, and we'll do a lot more of these, going forward. Jay, thank you so much for joining me, and, we'll see each other soon.

Thanks very much, Derk. Appreciate it.